<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70685">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149641</url>
  </required_header>
  <id_info>
    <org_study_id>CCR2608</org_study_id>
    <nct_id>NCT02149641</nct_id>
  </id_info>
  <brief_title>Parotid-sparing IMRT for Nasopharyngeal Cancer</brief_title>
  <official_title>Phase II Study of Parotid Sparing IMRT for Nasopharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <authority>United Kingdom: Royal Marsden CCR and Local and National Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the treatment of nasopharyngeal cancers, to determine the incidence of high grade  (≥G2)
      subjective xerostomia at 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to determine the feasibility in delivering induction
      chemotherapy and concomitant chemotherapy with IMRT in the treatment of locally advanced
      nasopharyngeal cancers and to determine the incidence of high grade (≥G2) subjective
      xerostomia at 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>the incidence of ≥G2 xerostomia at 1 year using the subjective component LENTSOMA</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute radiation toxicities</measure>
    <time_frame>0-3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late radiation toxicities</measure>
    <time_frame>3-24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>loco-regional disease-free survival (LRDFS), progression-free survival (PFS) and overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemotherapy compliance and toxicities</measure>
    <time_frame>0-12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Nasopharyngeal Cancers</condition>
  <condition>Intensity Modulated Radiotherapy With Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Nasopharyngeal cancers</arm_group_label>
    <description>Intensitiy modulated radiotherapy with chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity modulated radiotherapy with chemotherapy</intervention_name>
    <arm_group_label>Nasopharyngeal cancers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        nasopharyngeal cancers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nasopharyngeal cancers

        Exclusion Criteria:

          -  Patients &lt;16 years old or with a previous malignancy other than non-melanomatous skin
             cancer were excluded
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher M Nutting, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>May 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
